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ABSTRACT  1 
Objective. To study the effect of human plasma from different sources such as 2 
umbilical cord blood and adult blood platelet-rich plasma (PRP) on the 3 
regeneration of endometrial damage. 4 
Design. Composition analysis, in vitro approaches and a pre-clinical murine 5 
model using plasma to promote endometrial regeneration. 6 
Setting. Hospital and university laboratories. 7 
Patients/Animals. Adult plasma from 4 A8 
Atrophy patients and one fertile woman, commercial umbilical cord plasma and9 
uterine-damaged NOD/SCID mice model were used. 10 
Intervention(s). Endometrial stromal cells from primary culture and an 11 
endometrial stem cell line were cultured in vitro and uterine-damaged 12 
NOD/SCID mice were treated with plasma samples from several origins. 13 
Main Outcome Measure(s). All plasma samples contain molecules with a high 14 
potential for regeneration (SCF, PDGFBB, THBS1, VWF). Furthermore, the 15 
highest increase in in vitro proliferation and migration rate was found when 16 
endometrial stromal cells were treated with umbilical cord plasma, adult PRP 17 
also revealed a significant increment. In the mouse model, a higher expression 18 
of Ki67 and Hoxa10 in the endometrium was detected after applying adult PRP 19 
and the proteomic analysis revealed a specific protein expression profile 20 
depending on the treatment. The damaged uterine tissue showed more pro-21 
regenerative markers after applying umbilical cord plasma (Stat5a, Uba3, Thy1) 22 
in comparison to the other treatments (non-activated umbilical cord plasma, 23 






































































Conclusion. Human PRP possesses regeneration properties usable for 1 
endometrial pathologies. Besides that, these regenerative effects seem to be 2 
more apparent when the source of obtaining is umbilical cord blood. 3 
Keywords: -rich plasma, 4 









































































The endometrium is an extremely regenerative and complex tissue lining the 2 
uterus. It is responsible for embryo implantation and the success of the future 3 
pregnancy during the female reproductive life (1,2). However, some disorders 4 
affecting this tissue can complicate the implantation process (3 5). In this 5 
context, trophy (EA) are relevant 6 
endometrial pathologies causing these types of fertility problems. AS is defined 7 
by the presence of intrauterine adhesions, which contribute to a partial or 8 
complete absence of functional endometrium (6), while EA is characterized by 9 
insufficient endometrial growth (7). Women suffering from AS or EA have a10 
lower probability of a successful pregnancy because of impaired implantation 11 
and early abortion (8). However, until now, there has not been a completely 12 
effective and reliable therapy. Different treatments have been proposed (7), but 13 
only stem cell therapy has shown any effectiveness (9 14). Nevertheless, this 14 
kind of treatment implies invasive and expensive procedures. For this reason, 15 
the medical and scientific community is still looking for alternative and cost-16 
effective therapies. In the last years, platelet-rich plasma (PRP) has been 17 
proposed as a promising alternative: PRP can easily be isolated and applied 18 
non-invasively and moreover this can be done autologously.19 
Over the last two decades, PRP has been used in different medical fields 20 
ranging from dermatology to dental surgery (15 17). PRP is a plasma fraction 21 
with a platelet concentration above the normal average (~200.000 platelets/µl) 22 
(18) -granules deliver, after activation, cytokines, 23 
chemokines, and different growth factors such as platelet-derived growth factor 24 






































































(HGF), transforming growth factor beta ( ), or stromal cell-derived factor 1 1 
alpha (SDF1 ). Therefore, PRP is enriched in these factors (18,19), which play 2 
a crucial role in the recruitment of different cell types that proliferate and migrate 3 
towards the injured site, promoting tissue regeneration and angiogenesis 4 
(18,20).5 
More recently, PRP has started to be used in reproductive medicine. Different 6 
groups have shown positive results using in vitro experiments using human 7 
endometrial cells (21 23). Furthermore, rodent models have also shown 8 
promising results, describing how PRP administration in damaged uterine horns 9 
enhances cell proliferation, reduces fibrosis, and even increases implantation 10 
sites (24,25). Some proof of concepts  in humans have been carried out too, 11 
instilling autologous PRP in patients with a thin endometrium (26 28). However, 12 
there is still a need for a profound understanding of its mechanism of action.13 
Going one step forward, PRP can be obtained not only from adult peripheral 14 
blood, but also from umbilical cord blood (UCB). It has been generally 15 
considered that the younger the source, the higher its regenerative potential is.16 
It is thought to be linked to the higher concentration of growth and pro-17 
angiogenic factors found in comparison to plasma from an older source (29).18 
This has been illustrated functionally using in vitro (30,31) and in vivo (32,33) 19 
assays. There are also several ongoing clinical trials using umbilical cord PRP 20 
(34 36). 21 
In this pilot study, we developed novel in vitro and in vivo models to investigate 22 
the possible beneficial effects of PRP from AS/EA patients. Using both 23 
approaches we aimed to compare if plasma from human UCB had a stronger 24 






































































afflictions. We also aimed to ensure that PRP from AS/EA patients was as 1 
effective as the one from a healthy woman and thus could be used for 2 








































































MATERIAL AND METHODS 1 
Study design 2 
An overview of our study is detailed in Figure 1. After extracting peripheral 3 
blood (PB) from patients with endometrial pathologies (n=4) and a control 4 
(fertile female, n=1), PRP was prepared (Figure 1A). Commercial umbilical cord5 
plasma (STEMCELL Technologies, Catalog #70020.2, Lot. #1706230142) was 6 
also prepared (Figure 1B). The product information we received revealed a 7 
female Caucasian donor who tested negative for HIV-1 and 2, and Hepatitis B 8 
and C. The product was obtained using consent forms and protocols approved 9 
by either the Food and Drug Administration or an Institutional Review Board.10 
Part of these samples were activated with 0.1 M calcium chloride (CaCl2)11 
(Sigma Aldrich, Catalog #21115), for inducing platelet degranulation and growth 12 
factors and other signaling molecules secretion. Then, samples were used for 3 13 
different experiments (Figure 1B). First, Liquid Chromatography coupled to 14 
Mass Spectrometry (LC-MS/MS) and multiplex protein immunoassays were 15 
used for analyzing the specific plasma composition. Secondly, an in vitro16 
approach for measuring cell proliferation and migration was developed to17 
demonstrate the plasma effect over key cellular processes involved in tissue 18 
regeneration. Finally, an Asherman Syndrome (AS) murine model was 19 
employed, where the uterine horns were analyzed by Sequential Window 20 
Acquisition of All Theoretical-Mass Spectra (SWATH-MS) to evaluate if plasma 21 
was able to recover damaged uterine horns. 22 
Human plasma samples and PRP preparation 23 
PB samples were collected from 4 different AS/EA patients (diagnosed by 24 






































































fertility; all of them aged between 34 and 49 provided informed consent. This 1 
study was approved by the Clinical Ethics Committee of IVI Valencia (1707-2 
FIVI-003-IC). 3 
To isolate PRP, all PB samples were sequentially centrifuged (280g/8min/RT 4 
followed by 400g/15min/RT) and the PRP (upper part) and platelet-poor plasma 5 
(PPP, lower part) fractions were collected (Figure 1A). Then, all patient samples 6 
(aPRP), part of the PRP control (aPRPC) and part of the umbilical cord plasma 7 
(aUCP) were activated using 5% of CaCl2 0.1 M.  8 
Adult PRP and UCP analysis by proteomic analysis 9 
LC-MS/MS technique was performed as described elsewhere (37). Briefly, all 10 
samples were loaded into a 1D SDS-PAGE gel and LC-MS/MS analysis was 11 
performed, eluted peptides were analyzed in a nanoESI qQTOF mass 12 
spectrometer and all the fragments were combined in a single search using 13 
ProteinPilot v.5.0 and the Swissprot database.  14 
Two immunoassays, covering 46 different analytes (Supplemental Table 1),15 
were performed in all samples: Cytokine/Chemokine/Growth Factor 45-Plex 16 
-17 
Kit (Thermo Fisher Scientific, catalog #EPX450-12171-901 and #EPX01A-18 
10249-901). Quantification was carried out using a Luminex MagPix system and 19 
Luminex xPonent Software.20 
In vitro evaluation of cell proliferation and migration assays  21 
Both assays were performed with two different cell types: a human stromal stem 22 
cell line, ICE7 (n=3), obtained by using Hoescht methodology previously 23 






































































from endometrial biopsies from healthy oocyte donors (n=10) (38). In both 1 
assays, 3 conditions (No Treatment, aPRP and aUCP) were studied.2 
Furthermore, in the cell proliferation assay using ICE7 cells we performed some 3 
preliminary tests: 3 more conditions were included (aPRPC, naPRPC and 4 
aPPP) to check the optimal concentration (1%, 5%, 10% or 20%) of treatment in 5 
the culture media. 6 
For viable cell proliferation assay, cells were seeded in a 96-well plate and 7 
incubated overnight with DMEM supplemented with 10% fetal bovine serum 8 
(FBS). Thereafter, CellTiter 96® AQueous One Solution Reagent (Promega, 9 
catalog #G3580), containing a tetrazolium compound (MTS), was added and 10 
absorbance (490nm) was measured to evaluate viable cell proliferation. 11 
For the wound healing assay, cells were seeded in 24-well plates with DMEM 12 
supplemented with 10% FBS and grown to confluence. The monolayer was 13 
then scratched using a pipette tip. After washing the wells with phosphate-14 
buffered saline solution for removing detached cells, corresponding treatments 15 
were added and cells were photographed 0, 24 and 48 hours after scratching 16 
and the wound area was quantified using Image J software.17 
In vivo experiments: proteomic profiles and endometrial regeneration in an AS 18 
animal model  19 
In vivo procedures were performed in female eight-week-old NOD-SCID mice 20 
(Charles River Laboratories), according to the Ethics Committee for Animal 21 
Welfare (A1483088947170) of the University of Valencia (Spain). An adaptation 22 
from our previous protocol (12) was followed: damage was induced inside the 23 






































































undamaged (control). Mice were distributed in 4 groups and all of them 1 
underwent the same protocol: 3 successive injections (day 0, 2 and 4) through 2 
the tail vein, a each, and they were euthanized on 3 
day 7 (Figure 1B). The four groups were: No treatment group (n=6, milliQ H20),4 
naUCP group (n=6), aUCP group (n=6) and aPRP group (n=9). Mice from the 5 
last group were treated with aPRP from 4 different patients (3 aPRP were 6 
injected in 2 animals each for SWATH-MS and the fourth aPRP, in the 7 
remaining animals). Endometrial tissue from both horns of 6 mice/group (n=48)8 
was analyzed by SWATH-MS. We used the remaining mice (n=3) from aPRP 9 
group for a preliminary test before proceeding with the SWATH-MS analysis. 10 
Moreover, endometrial tissues were tested for Ki-67 (a cell proliferation marker) 11 
and Hoxa10 (a transcription factor directly related to endometrium function and 12 
development) signals, to demonstrate the pro-regenerative events.  13 
Ki67 signal (1:100, Abcam, catalog #ab833) was measured by 14 
immunohistochemistry and Hoxa10 by Western Blot (WB) (1:100 SantaCruz, 15 
catalog #sc-281428). Image ProPlus (Media Cybernetics) and ImageJ software 16 
were respectively used for quantification. 17 
Relative quantification of murine protein endometrial tissues by SWATH  18 
SWATH-MS procedure was carried out as described elsewhere (39). Briefly, all 19 
samples were pooled to build the spectral library from a 1D SDS-PAGE gel, and 20 
resulting peptides were analyzed in a nanoESI qQTOF mass spectrometer. 21 
Then, tripleTOF was operated in SWATH mode for individual samples. Data 22 
were analyzed using Peak View 2.1 and Marker View. Protein areas were 23 
normalized by the total sum of the areas of all the quantified proteins. After 24 






































































Functional in silico analysis 1 
For proteomic data analysis, Gene Ontology (GO) (40) and Kyoto Encyclopedia 2 
of Genes and Genomes (KEGG) (41) databases were considered through 3 
g:Profiler tool set (42),  Genemania (43) and, KEGG mapper4 
web tools. 5 
Statistical analysis 6 
Data were analyzed using GraphPad Prism 7.04 software and presented as 7 
mean + standard deviation (SD) or median ± interquartile range (IQR), when 8 
required. An analysis of variance was used to analyze cell proliferation and 9 
wound closure rates and growth factors/cytokine/chemokine concentrations. A 10 
Mann Whitney test was used to analyze Ki67 and Hoxa10 signals. P<0.05 was 11 
considered statistically significant. 12 
SWATH-MS data were analyzed using multinomial regression with Elastic Net 13 
penalization (Elastic Net .5) (44).14 
RESULTS 15 
Comprehensive proteomic evaluation of plasma from different sources  16 
The LC-MS/MS proteomic analysis showed the presence of 616 proteins in 17 
aUCP, 331 in naUCP and 237 in aPRP samples. Only proteins detected in at 18 
least 2 of the aPRP samples were considered (Figure 2A). The functional in 19 
silico analysis revealed no relevant differences among PRP from patients and 20 
control (data not included), revealing that plasma from AS/EA patients is not 21 






































































According to the objective of this study, we were interested in proteins related to 1 
tissue regeneration (45,46), specifically those localized -2 
granules. Among all the proteins detected, thrombospondin-1 (THBS1), -2-3 
macroglobulin (A2M), von Willebrand factor (VWF), neural cell adhesion 4 
molecule 1 (NCAM1), or insulin-like growth factor II (IGF2) were found in all 5 
plasma samples. Meanwhile, other interesting proteins such as CD109 antigen,6 
insulin-like growth factor-binding protein 4 (IGFBP4), and angiopoietin-related 7 
protein 3 (ANGPTL3) were detected only in naUCP; multimerin-1 (MMRN1), 8 
pyruvate kinase (PKM) and peroxiredoxin-1 (PRDX1) were exclusively found in 9 
aUCP. Finally, adenosine deaminase 2 (ADA2), 14-3-3 protein gamma 10 
(YWHAG), and macrophage migration inhibitory factor (MIF) were only found in 11 
aPRP (Figure 2A). To note that due to the big difference between aUCP and 12 
naUCP composition, we continued our analysis only with the activated fraction. 13 
KEGG pathway analysis was performed only for aUCP and aPRP samples. The 14 
analysis revealed that among others, PI3K-Akt signaling pathway was shared 15 
by proteins detected in both samples. Hippo pathway only appeared in aUCP 16 
fraction while MAPK and Rap1pathways, in aPRP fractions (Figure 2B).  17 
Growth factors, interleukins and chemokines in plasma samples 18 
The results of the arrays revealed a statistically higher concentration (pg/mL) of 19 
several growth factors in both aUCP(*) and naUCP(**) fractions when compared 20 
with aPRP. These growth factors were  (P=0.0048*; P=0.0024**), kit 21 
ligand or SCF (P=0.0001*; P<0.0001**), PDGFBB (P=0.0008*; P=0.0024**),22 
HGF (P=0.0005*; P=0.0003**), and VEGFD (P=0.0011*; P=0.0006**) (Figure 23 
2C). From all the cytokines and chemokines studied, we detected IL2, IL7, IL15, 24 






































































1 (MCP1) and  in all samples. However, only IL1-RA (P=0.0060*; 1 
P=0.0010**) and IL15 (P=0.0026) presented statistically differential results; to 2 
note that IL15 was the only molecule with a significantly higher concentration in 3 
aPRP (Figure 2C). A complete list of the analyzed molecules and the values4 
obtained can be found in Supplemental Table 1. 5 
Increased in vitro cell proliferation and migration after treating cells with plasma 6 
To measure viable cell proliferation rates, we first performed MTS assays. The 7 
preliminary tests using ICE7 cells revealed that the highest rate was found in 8 
the presence of 1% plasma in the culture media (P=0.0015) (Figure 3A) and 9 
reaffirmed the higher potential of aPRP (P=0.0034) to stimulate cell proliferation 10 
compared to aPPP (Figure 3B). These initial tests also reinforced the positive 11 
effect of the activation process, when comparing aPRPC (P=0.0171) and12 
naPRPC with the No Treatment condition (Figure 3B). As seen on Figure 3B, 13 
aPRPC (fold change, FC = 1.20) seems to have a similar effect than aPRP (FC14 
= 1.26), confirming that plasma from AS/EA patients is not affected. 15 
Secondly, in the main proliferation assay using ICE7, proliferation rates from16 
aPRP (P=0.0380) and aUCP (P=0.0042) conditions were significantly higher 17 
compared with the No Treatment condition. Furthermore, this increment was18 
higher when applying aUCP (FC = 1.36) instead of aPRP (FC = 1.22) (Figure 19 
3C). These results were reproducible when using primary stromal cells 20 
(hESCs). Cell proliferation was significantly incremented with the addition of 21 
aPRP (P=0.0394) and aUCP (P<0.0001) to the culture media. In this case, 22 
aPRP proliferation rate increased by a 1.30 fold change and aUCP, by 1.80 fold 23 






































































Regarding the wound healing assay, results appeared to generally corroborate 1 
these previous results, despite being not statistically significant. There was a2 
noticeable higher trend to cover the initial gap (in % of gap closure 24 hours 3 
after the wound) when cells were treated with aPRP (42.20 %) or aUCP (49.40 4 
%) in comparison with the No Treatment condition (38.77 %), using ICE7 5 
(Figure 3E, upper part). This effect was also reproducible with hESCs where 6 
aPRP (50.78 %) and aUCP (53.69 %) seemed to induce a higher wound 7 
closure rate than the No Treatment condition (42.52 %) (Figure 3E, lower part).8 
In vivo increased expression of cell proliferation and endometrial markers after 9 
applying aPRP  10 
A preliminary test performed in the animal model revealed that aPRP was likely 11 
promoting tissue regeneration. The Ki67 immunoassay, which evaluates the cell 12 
proliferation rate, showed an increased significant signal (P=0.0106) in the 13 
damaged horns when compared to the control ones from aPRP group (Figure 14 
4A, left). Hoxa10, an important transcription factor for many genes involved in 15 
the endometrial function and development, measured by WB also showed a 16 
more intense signal in damaged versus control horns (Figure 4A, right), without 17 
being statistically significant. 18 
Relative protein quantification in murine uterine horns revealed aUCP as the 19 
gold standard treatment   20 
The SWATH-MS analysis of the right and left uterine horns (n=48) from all mice 21 
groups (No treatment, aPRP, naUCP and aUCP) revealed the presence of 2766 22 
different tissue proteins. We performed a statistical analysis using 2 different 23 






































































naUCP and aUCP groups separately, and secondly, the damaged horns in 1 
each group against damaged ones in the rest of the groups. A detailed list of 2 
the differentially expressed proteins (DEP) after performing both approaches is 3 
shown in Supplemental Table 2. 4 
When we globally analyzed the abundance of proteins in both horns, the 5 
damaged and control group profiles were clearly distinguishable (Figure 4B).6 
Interestingly, we found that the up-regulated proteins in the damaged horns of 7 
the aUCP group were implicated in different events related to tissue 8 
regeneration such as PI3K-Akt, TGF  or JAK-STAT signaling pathways. These 9 
proteins were a subunit of phosphatidylinositol 3-kinase), 2aaa (Pr6510 
subunit of protein phosphatase 2A), Stat5a (a signal transducer and activator of 11 
transcription) and Rhoa (a small GTPase). To note that the up-regulated 12 
proteins in the damaged horns of the other groups, aPRP and aUCP, were not 13 
involved in the signaling pathways mentioned here. 14 
When we only analyzed the damaged horns, proteins seemed to group 15 
depending on the treatment applied (Figure 4C). When analyzing these proteins 16 
in-depth, damaged horns from group C (aUCP) showed an up-regulation of 17 
Uba3 (NEDD8-activating enzyme E1 catalytic subunit), Thy1 (CD90 antigen),18 
Rnh1 (ribonuclease inhibitor) and Atpo (mitochondrial membrane ATP 19 
synthase). These last 2 proteins, together with Ppp1ca (protein phosphatase) 20 
and Golga2 (Golgin subfamily A member 2), were upregulated in group D21 
(aPRP). Atp1b3 (a subunit of a sodium/potassium-transporting ATPase) was 22 
up-regulated in group B (naUCP) and Cklf6 (member of the chemokine-like 23 







































































WB analysis of several of these DEP, in both approaches, corroborated the 1 
regulation pattern of these proteins (Supplemental Figure 1). The selected2 
proteins were Cklg6, Golga2, Uba3, Atp1b3, the cytosolic Fe-S cluster 3 
assembly factor 4 
256 (Tmem256). 5 
DISCUSSION  6 
Along this study, we reinforced the regenerative potential of plasma depending 7 
on its specific composition or source. This was done via assessing endometrial 8 
cell proliferation and migration in in vitro assays and tissue regeneration in an 9 
AS murine model. We also demonstrated via proteomic analysis the superior 10 
potential of the UCB over the adult blood as a source of regenerative plasma. 11 
The main goal in patients affected with either AS or EA is to regenerate the 12 
endometrial tissue, restoring its normal proliferation rate and thickness. Thus, it 13 
is necessary to trigger the complex regeneration process which includes distinct 14 
events such as angiogenesis, cell recruitment, matrix deposition and 15 
inflammation (47). We postulate here that the presence and concentration of16 
several growth factors, chemokines and cytokines change with the age of the 17 
plasma and PRP could play a role in these kinds of processes. We also 18 
demonstrated that the (adult or UCB) origin affected the concentration of some 19 
of these molecules. Among these, a potent mitogen (HGF) and other growth 20 
factors involved in cell chemotaxis and proliferative activities (PDGFBB, SCF), 21 
events involving angiogenesis ( ) and the inflammatory response 22 
(IL1-RA), had a statistically significant higher concentration in UCP (in both 23 
a/na) (29,30), providing a higher regenerative ability, while IL2, IL7 and IL15 24 






































































pro-inflammatory cytokines could be explained by the immune immaturity of the 1 
UCB (29,48), a characteristic that, added to the fact that plasma is an acellular 2 
blood fraction, completely minimize any kind of immunological issue, mainly a 3 
rejection reaction when using UCB (49). These results complement previous 4 
studies where a detrimental effect of aging in plasma was shown (32,50).5 
Castellano et al. demonstrated that UCP could regenerate hippocampal function 6 
in aged mice (32) better than adult plasma via specific key factors. These 7 
proteins were also detected only (or with a higher score) in the UCP samples, 8 
corroborating the results of in this study. The in silico functional analysis of 9 
these plasma proteins showed different signaling pathways involved in cell 10 
proliferation, differentiation and migration, such as the PI3K-Akt pathway, that 11 
could be triggering the regeneration processes. The identification of these 12 
pathways also correlates with our in vitro results where an increase in cell 13 
proliferation and migration rates was seen when adding PRP to the medium, 14 
with UCP outperforming the other groups. 15 
Some studies already demonstrated the beneficial effect of adult PRP over 16 
animal models with induced uterine damage (24,25), however none included 17 
the younger UCP as done in this study. In our AS murine model, after a deep 18 
analysis of the protein patterns of the uterine tissue, we established that aUCP 19 
produced major changes in the protein abundance tissue pattern. The functional 20 
analysis revealed that the up-regulated proteins in the aUCP group were mainly 21 
involved in the regulation of angiogenesis and mitotic cell cycle: Uba3, 22 
described as essential for NEDD8-mediated neddylation that is required for 23 
normal human endometrial function (51); Thy1/CD90, a well-known endometrial 24 






































































been described as down-regulated in endometrial glands in endometriotic 1 
versus healthy endometrium samples (52). Besides, when comparing the 2 
damaged versus the control uterine horns in the aUCP group, up-regulated 3 
proteins such as Stat5a (a mediator of cell response to SCF and other growth 4 
factors), were also involved in PI3K-Akt and JAK-STAT pathways, as the 5 
plasma proteins, but in further steps of the cascades. 6 
Considering this study as pioneer in the use of umbilical cord blood plasma in 7 
the endometrial field even using pre-clinical murine models, we are aware about8 
several limitations to this work. Since plasmas samples were not very easy to 9 
obtain, our sample size was small. Despite the wound healing assay is the most 10 
widely used, several restrictions such as injure/stress/non- proliferation 11 
processes affecting cell migration have been described after performing the 12 
scratch. Other options related to this issue should be further explored, either 13 
with longer exposure times or with other types of migration assays. 14 
Conclusions 15 
Given the specific mechanisms described above, it becomes apparent that PRP 16 
is a promising regenerative enhancer, especially when using UCB. Activated 17 
UCP revealed to be the best treatment in 3 different scenarios: analysis of 18 
plasma composition (higher concentrations of key molecules involved in pro-19 
regenerative processes), in vitro evaluation of cell proliferation, and migration 20 
and uterine tissue analysis in an AS murine model. Nonetheless, despite that 21 
autologous PRP has already started to be used in human patients suffering 22 
from AS/EA (27,28,53 55), specific clinical studies are needed to reinforce the 23 
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FIGURE LEGENDS 1 
Figure 1. Study design. (A) Platelet-rich plasma (PRP) preparation procedure 2 
from peripheral blood. Once isolated, it was activated (if necessary) using 5% of 3 
CaCl2 0.1M, aliquoted and stored at -80ºC. (B) Overview of the different assays 4 
and analysis performed using PRP from 3 different sources: commercial plasma 5 
from umbilical cord blood, 4 different As  syndrome (AS)/Endometrial 6 
Atrophy (EA) patients and a control patient (healthy). Briefly, all plasmas were 7 
analyzed by LC-MS/MS and multiplex protein assays and used for 2 different in 8 
vitro assays (MTS and wound healing) using 2 different human endometrial 9 
stromal cell types (from a stem cell line and from primary culture) and for an 10 
animal model (mice uterine horns were analyzed by SWATH-MS proteomic 11 
procedure and by several protein assays). 12 
Figure 2. Composition analysis of plasmas. (A) Venn diagram showing the 13 
number of common proteins between the activated and the non-activated 14 
fraction in UCP and the proteins present in all aPRP samples. (B) Venn 15 
diagram showing the shared KEGG pathways among the proteins detected by 16 
LC/MSMS in the aUCP and aPRP. (C) Multiplex protein assays results for 17 
cytokines, chemokines and growth factors are also shown, for the different 18 
samples analyzed. Data are presented as mean + standard deviation (SD).  19 
*P<0.05 in aUCP vs aPRP; **P<0.05 in n P<0.05 in aPRP vs 20 
UCP(a/na). 21 
Figure 3. In vitro assays: cell proliferation and migration assays. (A)22 
Assessment of optimal concentration to supplement culture media. (B) Proof-of-23 
concept MTS (proliferation assay) results in ICE7 line: comparison of cell 24 






































































activated PRPC samples. (C) MTS results using human endometrial stromal 1 
stem cells (ICE7, n=3) and (D) human endometrial stromal cells (hESCs, n=10). 2 
(E) Wound healing (cell migration) assays results using ICE7 stem cell line 3 
(n=3) and hESCs (n=10). Data are presented as mean + standard deviation 4 
(SD).  *P<0.05 5 
Figure 4. In vivo assays: AS/EA murine model. (A) Proof-of-concept: after 6 
aPRP treatment, Ki67 immunostaining was performed in uterine tissue sections 7 
(20X magnification) and Hoxa10 western blot performed from protein extracts of 8 
uterine horns. Data are presented as median ± interquartile range (IQR). (B)9 
Heatmap of SWATH-MS data showing protein presence between damaged and10 
undamaged horns. Up-regulated proteins related to the KEGG pathways in the 11 
graphs below are highlighted in bold. The other proteins were also detected in 12 
the comparison among the 4 types of damaged horns and/or validated by 13 
Western blot. (C) Left: heatmap of SWATH-MS results after Elastic Net 14 
penalization comparing damaged horns from the 4 groups. Proteins related to 15 
pro-regenerative events are highlighted in bold. Right: network (GeneMania) 16 
showing the interactions among the differentially expressed proteins in the17 
different groups. *P <0.05. 18 
SUPPLEMENTAL FIGURES AND TABLES 19 
Supplemental figure 1. Validation of Elastic Net regularization SWATH-MS 20 
results by Western Blot. (A) Western blot bands for one validated protein 21 
among the up-regulated ones in each of the groups (comparison between22 
damaged horns from the 4 groups): Cklf6 (No Treatment), Golga2 (aPRP), 23 
Uba3 (aUCP) and At1b3 (naUCP). (B) Graph showing the relative area 24 






































































(one down- and 2 up-regulated when comparing damaged versus control horns) 1 
in the aPRP group (comparison between both horns from naUCP, aUCP and 2 
aPRP groups (D) Graph 3 
showing the relative area measurement (ImageJ software). Data are presented 4 
as mean + standard deviation (SD).  *P<0.05. Narrows indicate the group (part 5 
B) or horn (part D) in which the protein expression value was higher. 6 
SUPPLEMENTAL TABLES 7 
Supplemental table 1. Multiplex protein assays results of the analyzed 8 
plasmas. Protein targets included in the multiplex assays and the concentration 9 
values detected in analyzed samples. Blue wells show those factors that were 10 
statistically significant among the umbilical cord samples and the adult samples. 11 
Supplemental table 2. SWATH-MS statistics results. Enumeration, including12 
the ElasticNet coefficient, of the statistically differentiated proteins when 13 
performing the intergroup comparison among all damaged horns and the 14 
intragroup comparison in the naUCP, aUCP and aPRP groups. In blue, 15 



























































































TARGET PROTEINS COMPLETE NAME aUCP naUCP aPRP
GM CSF Granulocyte-macrophage colony-stimulating factor UDL UDL UDL
Interferon gamma UDL UDL UDL
Interleukin-1 beta 2.63 3.25 6.49
IL 12 p70 Interleukin-12, p70 UDL UDL UDL
IL13 Interleukin-13 17.65 UDL UDL
IL18 Interleukin-18 225.04 322.31 312.57
IL2 Interleukin-2 14.93 18.99 20.06
IL4 Interleukin-4 UDL UDL UDL
IL5 Interleukin-5 18.88 6.30 UDL
IL6 Interleukin-6 UDL UDL UDL
Tumor necrosis factor alpha UDL UDL UDL
IL10 Interleukin-10 UDL UDL UDL
IL17A Interleukin-17A 17.55 8.07 UDL
IL21 Interleukin-21 UDL UDL UDL
IL22 Interleukin-22 UDL UDL UDL
IL23 Interleukin-23 UDL UDL UDL
IL27 Interleukin-7 UDL UDL UDL
IL9 Interleukin-9 UDL UDL UDL
Interferon alpha UDL UDL UDL
Interleukin-1 alpha UDL UDL UDL
IL1RA Interleukin-1 receptor type 1 991.07 1101.37 534.29
IL15 Interleukin-4 6.94 4.86 27.54
IL31 Interleukin-31 UDL UDL UDL
IL7 Interleukin-7 7.19 6.69 9.83
TNF beta Lymphotoxin-alpha NA NA NA
eotaxin Eotaxin 37.54 43.13 33.23
gro alpha/KC Growth-regulated alpha protein UDL UDL UDL
IL8 Interleukin-8 UDL UDL UDL
IP10 C-X-C motif chemokine 10 UDL 50.82 60.03
MCP1 C-C motif chemokine 2 104.83 118.20 74.71
C-C motif chemokine 3 UDL UDL UDL
C-C motif chemokine 4 UDL UDL UDL
RANTES Regulated on Activation, Normal T Cell Expressed and Secreted, C-C motif chemokine 5 NA NA NA
Stromal cell-derived factor 1 483.64 308.48 588.13
BDNF Brain-derived neurotrophic factor 217.21 205.15 425.96
b NGF Beta-nerve growth factor 311.38 308.40 756.45
EGF Epidermal growth factor 19.76 20.95 63.87
FGF2 Fibroblast growth factor 2 9.27 UDL UDL
HGF Hepatocyte growth factor receptor 382.79 398.94 87.56
LIF Leukemia inhibitory factor 25.95 24.16 25.86
PDGF BB Platelet-derived growth factor subunit B 3702.54 4523.90 2312.27
PIGF Phosphatidylinositol-glycan biosynthesis class F protein 134.13 128.94 160.93
SCF Kit ligand 31.25 40.13 6.84
VEGF A Vascular endothelial growth factor A 291.08 371.90 192.14
VEGF D Vascular endothelial growth factor D 33.23 34.91 16.15
Transforming growth factor beta 2449.06 441.12 1340.79






























Coefficient aPRP Coefficient No Treatment
3.63E-08 4.00E-08
-3.22E-04 4.77E-05
-4.56E-06 2.09E-06
-1.14E-06 2.41E-07
-7.84E-05 8.72E-05
-8.31E-06 1.27E-05
2.47E-06 -1.01E-06
1.58E-05 -2.46E-05
-1.98E-06 -5.32E-07
-2.25E-07 -4.09E-08
-9.91E-06 -1.67E-06
-6.77E-06 -8.83E-06
-1.47E-06 -9.66E-06
1.04E-05 1.01E-05
-8.29E-06 1.79E-05
-1.06E-06 2.06E-06
-1.39E-06 1.87E-06
7.91E-07 -9.49E-07
2.14E-05 -2.41E-06
3.59E-06 -1.05E-05
3.32E-06 -4.15E-07
1.83E-05 -5.59E-06
-1.31E-08 -1.57E-07
-1.89E-07 -4.13E-07
-1.91E-06 -1.23E-06
-7.11E-07 -1.54E-06
-9.06E-08 -2.94E-06
-9.26E-07 -1.34E-05
-4.01E-05 -1.65E-05
Proteins Coefficient
sp|Q9JII5|DAZP1_MOUSE 8.68E-01
sp|P35282|RAB21_MOUSE 8.51E-01
sp|P14824|ANXA6_MOUSE 8.38E-01
sp|Q9D892|ITPA_MOUSE 5.41E-01
sp|Q99LY9|NDUS5_MOUSE 4.83E-01
sp|Q61074|PPM1G_MOUSE 4.71E-01
sp|Q8C460|ERI3_MOUSE 4.64E-01
sp|Q8C7R4|UBA6_MOUSE 2.61E-01
sp|P19973|LSP1_MOUSE 2.29E-01
sp|Q9D6Y7|MSRA_MOUSE 1.80E-01
sp|P36916|GNL1_MOUSE 1.73E-01
sp|P32020|NLTP_MOUSE 1.63E-01
sp|P61089|UBE2N_MOUSE 1.48E-01
sp|Q9CQM5|TXD17_MOUSE 1.42E-01
sp|Q3TLP5|ECHD2_MOUSE 1.18E-01
sp|Q9D6F9|TBB4A_MOUSE 1.05E-01
sp|Q80YR5|SAFB2_MOUSE 7.21E-02
sp|P97390|VPS45_MOUSE 5.94E-02
sp|Q9JKY0|CNOT9_MOUSE 4.76E-02
sp|Q9QYY8|SPAST_MOUSE 4.16E-02
sp|Q6P8J2|SAT2_MOUSE 3.07E-02
sp|Q9CQR6|PPP6_MOUSE 2.72E-02
sp|Q8VCN9|TBCC_MOUSE 2.24E-02
sp|Q9CU62|SMC1A_MOUSE 1.78E-02
sp|Q99PU5|ACBG1_MOUSE 1.42E-02
sp|P70335|ROCK1_MOUSE 1.08E-02
sp|Q80TL7|MON2_MOUSE 4.50E-03
sp|Q922P9|GLYR1_MOUSE -1.61E-02
sp|O55028|BCKD_MOUSE -1.98E-02
sp|Q6P2B1|TNPO3_MOUSE -3.61E-02
sp|Q6NV83|SR140_MOUSE -4.85E-02
sp|P49615|CDK5_MOUSE -5.63E-02
sp|Q9ET01|PYGL_MOUSE -2.20E-01
sp|Q9R0N0|GALK1_MOUSE -3.73E-01
sp|Q8CHP8|PGP_MOUSE -9.68E-01
sp|Q9ESZ8|GTF2I_MOUSE -1.85E+00
Proteins Coefficient
sp|Q8BG05|ROA3_MOUSE 1.19E+00
sp|Q76MZ3|2AAA_MOUSE 6.66E-01
sp|Q9CZD3|GARS_MOUSE 4.28E-01
sp|Q8K1M6|DNM1L_MOUSE 4.08E-01
sp|P50544|ACADV_MOUSE 3.79E-01
sp|P56399|UBP5_MOUSE 3.76E-01
sp|Q8VCW8|ACSF2_MOUSE 3.31E-01
sp|P68368|TBA4A_MOUSE 3.16E-01
sp|Q91WQ3|SYYC_MOUSE 2.25E-01
sp|P08775|RPB1_MOUSE 1.75E-01
sp|Q9CWZ3|RBM8A_MOUSE 1.70E-01
sp|Q9ER88|RT29_MOUSE 1.59E-01
sp|Q9D880|TIM50_MOUSE 1.59E-01
sp|O08734|BAK_MOUSE 1.57E-01
sp|P53996|CNBP_MOUSE 1.52E-01
sp|P26450|P85A_MOUSE 1.36E-01
sp|P10107|ANXA1_MOUSE 1.20E-01
sp|Q9D379|HYEP_MOUSE 9.30E-02
sp|Q3U2P1|SC24A_MOUSE 6.88E-02
sp|P21958|TAP1_MOUSE 4.85E-02
sp|Q71FD7|FBLI1_MOUSE 4.83E-02
sp|Q9CR86|CHSP1_MOUSE 4.64E-02
sp|Q922L6|NELFD_MOUSE 4.35E-02
sp|Q8BI72|CARF_MOUSE 4.32E-02
sp|Q8K2B3|SDHA_MOUSE 3.78E-02
sp|P63242|IF5A1_MOUSE 3.77E-02
sp|P36552|HEM6_MOUSE 3.19E-02
sp|P42230|STA5A_MOUSE 2.71E-02
sp|Q8BWG8|ARRB1_MOUSE 2.58E-02
sp|P14824|ANXA6_MOUSE 2.53E-02
sp|Q8K3C3|LZIC_MOUSE 2.14E-02
sp|Q62523|ZYX_MOUSE 1.94E-02
sp|Q9QUI0|RHOA_MOUSE 1.37E-02
sp|P47968|RPIA_MOUSE 1.34E-02
sp|Q07113|MPRI_MOUSE 1.14E-02
sp|Q9Z2Q6|SEPT5_MOUSE 9.45E-03
sp|Q05186|RCN1_MOUSE 6.31E-03
sp|P31786|ACBP_MOUSE -1.61E-03
sp|Q61789|LAMA3_MOUSE -1.58E-02
sp|P60843|IF4A1_MOUSE -1.92E-02
sp|P99026|PSB4_MOUSE -2.81E-02
sp|Q9D8X2|CC124_MOUSE -4.62E-02
sp|Q06185|ATP5I_MOUSE -5.77E-02
sp|Q9D7B7|GPX8_MOUSE -6.39E-02
sp|Q3UZ39|LRRF1_MOUSE -7.65E-02
sp|Q921Y0|MOB1A_MOUSE -1.19E-01
sp|Q9WV98|TIM9_MOUSE -2.46E-01
sp|Q9R0P5|DEST_MOUSE -3.09E-01
sp|P62309|RUXG_MOUSE -3.96E-01
sp|Q8R016|BLMH_MOUSE -4.26E-01
sp|Q60692|PSB6_MOUSE -4.46E-01
sp|P56391|CX6B1_MOUSE -4.63E-01
sp|Q01768|NDKB_MOUSE -4.80E-01
sp|P63168|DYL1_MOUSE -5.89E-01
sp|P48758|CBR1_MOUSE -7.08E-01
Proteins Coefficient
sp|A2ASQ1|AGRIN_MOUSE 5.22E-01
sp|Q921M4|GOGA2_MOUSE 1.68E-01
sp|Q9D0R2|SYTC_MOUSE 1.61E-01
sp|Q8K4L3|SVIL_MOUSE 1.30E-01
sp|Q8VCK3|TBG2_MOUSE 9.76E-02
sp|P27601|GNA13_MOUSE 8.94E-02
sp|P97470|PP4C_MOUSE 8.84E-02
sp|Q99KJ8|DCTN2_MOUSE 8.68E-02
sp|Q80ZJ1|RAP2A_MOUSE 8.27E-02
sp|P47934|CACP_MOUSE 7.14E-02
sp|Q91VW3|SH3L3_MOUSE 6.79E-02
sp|Q8VE47|UBA5_MOUSE 6.71E-02
sp|Q9JLI6|SCLY_MOUSE 6.31E-02
sp|Q8VCF0|MAVS_MOUSE 5.61E-02
sp|Q9CQ91|NDUA3_MOUSE 5.27E-02
sp|Q91VI7|RINI_MOUSE 4.65E-02
sp|Q8BWY3|ERF1_MOUSE 3.71E-02
sp|Q78XR0|TPC6A_MOUSE 3.30E-02
sp|Q9JK38|GNA1_MOUSE 3.22E-02
sp|Q9JMA1|UBP14_MOUSE 2.76E-02
sp|Q5F285|TM256_MOUSE 1.01E-02
sp|Q99JT9|MTND_MOUSE 7.72E-03
sp|O35683|NDUA1_MOUSE 9.12E-04
sp|P28076|PSB9_MOUSE -1.50E-03
sp|P14131|RS16_MOUSE -1.93E-03
sp|Q60766|IRGM1_MOUSE -2.34E-03
sp|Q7TNP2|2AAB_MOUSE -3.58E-03
sp|Q9CRC8|LRC40_MOUSE -4.00E-03
sp|Q80Y17|L2GL1_MOUSE -1.23E-02
sp|Q9DBG1|CP27A_MOUSE -1.60E-02
sp|Q8JZM8|MUC4_MOUSE -2.04E-02
sp|Q9D0R8|LSM12_MOUSE -2.39E-02
sp|Q811D0|DLG1_MOUSE -3.94E-02
sp|P09470|ACE_MOUSE -7.97E-02
sp|Q8C7K6|PCYXL_MOUSE -8.07E-02
sp|P61211|ARL1_MOUSE -8.15E-02
sp|Q99LG2|TNPO2_MOUSE -1.09E-01
sp|A2ABV5|MED14_MOUSE -1.16E-01
sp|Q8R5F8|ES8L1_MOUSE -1.19E-01
sp|Q62470|ITA3_MOUSE -1.36E-01
sp|Q924K8|MTA3_MOUSE -1.39E-01
sp|Q8BMG7|RBGPR_MOUSE -1.54E-01
sp|Q9D8V0|HM13_MOUSE -1.59E-01
sp|Q9R062|GLYG_MOUSE -1.75E-01
sp|O35972|RM23_MOUSE -1.82E-01
sp|P53810|PIPNA_MOUSE -1.92E-01
sp|Q2EMV9|PAR14_MOUSE -2.77E-01
sp|Q9R061|NUBP2_MOUSE -2.98E-01
sp|Q9CQL5|RM18_MOUSE -2.98E-01
sp|Q91V09|WDR13_MOUSE -3.41E-01
sp|P84104|SRSF3_MOUSE -3.65E-01
sp|Q61510|TRI25_MOUSE -4.75E-01
